Moderna clinical trial data confirm its updated covid-19 vaccine generates strong immune response in humans against ba.2.86

Cdc notes that the ba.2.86 (pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated covid-19 vaccine for the fall 2023 season clinical trial data from research assay confirmed moderna's updated covid-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including ba.2.86, eg.5, and fl.1.5.1 variants with governments accelerating the timing of covid-19 vaccination campaigns due to the potential risk of ba.2.86, moderna has shared this data with regulators and is ready to supply its updated covid-19 vaccine pending regulatory approval cambridge, ma / accesswire / september 6, 2023 / moderna, inc. (nasdaq:mrna) today announced that clinical trial data from its research assay confirm its updated covid-19 vaccine, which is pending approval by the u.s. food and drug administration for the fall 2023 vaccination season, generates an 8.7-fold increase in neutralizing antibodies in humans against ba.2.86 (pirola), a variant under monitoring. the centers for disease control (cdc) indicates that the highly mutated ba.2.86 variant may be more capable of causing infection in people who previously had covid-19 or were vaccinated with previous vaccines, noting that updated covid-19 vaccines may be effective in reducing severe disease and hospitalization.
MRNA Ratings Summary
MRNA Quant Ranking